Science and technology firm Merck has made two appointments in two regions that are important for its biopharma business.
Gary Zieziula will lead Merck’s biopharma business in North America and Marc Horn will take the helm of the biopharma business in China.
Zieziula becomes President and Managing Director of the biopharma business in the US and Canada, based in Rockland, Massachusetts. He is responsible for all areas of the company’s business including driving overall strategic direction and maximising growth across the region.
Zieziula joined Merck in 2014 as Chief Commercial Officer in the US, having spent more than 30 years in the pharmaceutical industry, including senior level positions at MSD, Bristol Myers-Squibb, Roche and Amag Pharmaceuticals.
Marc Horn
Horn will head the biopharma business of Merck in China as of 1 April, as a Managing Director based in Beijing. He is currently the regional Chief Financial Officer (CFO) of Merck responsible for Eastern Asia, comprising China, Hong Kong, Japan, South Korea and Taiwan, for the three business sectors Healthcare, Life Science and Performance Materials.
Horn has more than 16 years of management experience in finance in the pharmaceuticals and chemicals industry, including positions at Bayer and Lanxess in Germany, China and Singapore.
Horn’s predecessor, Allan Gabor, has been promoted to President of the Asia-Pacific region for Merck’s biopharma business. In his new position, he will report to Gabor.
